| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
HIV-1
Elsulfavirine targets HIV-1 reverse transcriptase (RT), the enzyme responsible for converting viral RNA into DNA. As a non-nucleoside reverse transcriptase inhibitor (NNRTI), it binds to an allosteric site on the reverse transcriptase enzyme, causing a conformational change that inhibits its polymerase activity. This prevents the synthesis of viral DNA and subsequent viral replication. Resistance to Elsulfavirine is linked to mutations in the HIV-1 reverse transcriptase gene, which reduce binding affinity. |
|---|---|
| ln Vitro |
In vitro, Elsulfavirine shows potent antiviral activity against a wide range of HIV-1 strains, including those resistant to other NNRTIs. As an NNRTI, it inhibits HIV-1 reverse transcriptase activity, blocking viral DNA synthesis. The compound's activity against resistant strains suggests a favorable resistance profile. Its potency has been demonstrated in cell-based assays using HIV-1-infected cell lines.
|
| ln Vivo |
In vivo, Elsulfavirine has demonstrated potent antiviral activity against HIV-1. It received its first global approval in Russia in June 2017 for the treatment of HIV-1 infections in combination with other antiretroviral medicines. The compound's efficacy in clinical trials supports its use as part of combination antiretroviral therapy. Its activity against resistant strains suggests potential utility in treatment-experienced patients.
|
| Enzyme Assay |
In vitro enzyme assays for Elsulfavirine measure inhibition of HIV-1 reverse transcriptase activity. Recombinant HIV-1 RT enzyme is incubated with a template-primer (e.g., poly(rA)/oligo(dT)) and radiolabeled or fluorescently labeled nucleotides. Various concentrations of Elsulfavirine are added. Enzyme activity is measured by quantifying incorporated nucleotides. IC50 values are calculated from dose-response curves. Selectivity against HIV-2 RT and other polymerases is assessed.
|
| Cell Assay |
Cellular assays for Elsulfavirine use HIV-1-infected cell lines such as MT-4 or CEM cells. Cells are infected with HIV-1 at a defined multiplicity of infection and treated with various concentrations of Elsulfavirine. Viral replication is assessed by measuring HIV-1 p24 antigen levels in culture supernatant by ELISA, or by quantifying viral RNA by qRT-PCR. Cytotoxicity is assessed using MTT or ATP-lite assays. IC50 and CC50 values are calculated.
|
| Animal Protocol |
In vivo animal studies for Elsulfavirine typically utilize humanized mouse models or other small animal models of HIV-1 infection. The compound is administered orally at various doses. Viral load is measured in plasma over time. CD4+ T cell counts are monitored. Efficacy is compared to vehicle and reference antiretrovirals. Pharmacokinetic sampling is performed to correlate exposure with efficacy.
|
| ADME/Pharmacokinetics |
Elsulfavirine has molecular weight of 629.28 g/mol. As an NNRTI, it is orally bioavailable and has favorable pharmacokinetic properties. The compound's pharmacokinetic profile supports once-daily oral dosing. It is metabolized in the liver, primarily by CYP3A4, and has a long half-life suitable for once-daily administration. Drug-drug interaction potential with other antiretrovirals has been evaluated. Its approval in Russia confirms its clinical PK profile.
|
| Toxicity/Toxicokinetics |
Preclinical and clinical toxicity of Elsulfavirine has been evaluated to support regulatory approval. As an NNRTI, potential adverse effects include rash, hepatotoxicity, and central nervous system effects (dizziness, insomnia). The compound's safety profile in clinical trials supports its use in HIV-1 treatment. Drug interactions and resistance mutations are monitored. Standard toxicology studies would have been conducted for IND-enabling development.
|
| References | |
| Additional Infomation |
Elsulfavirine is being investigated in the clinical trial NCT03706898 (which aims to evaluate the safety and pharmacokinetics of Elpida® in healthy subjects and patients with impaired liver function, and to assess the effects of food intake and drug interactions with other antiviral drugs).
Elsulfavirine is a novel NNRTI for HIV-1 infection. It received its first global approval in Russia in June 2017 for HIV-1 treatment in combination with other antiretrovirals. It shows activity against resistant strains. Resistance is linked to RT mutations. It is available for research purposes and is a clinically approved drug in some regions. |
| Molecular Formula |
C24H17BRCL2FN3O5S
|
|---|---|
| Molecular Weight |
629.282285451889
|
| Exact Mass |
626.94
|
| Elemental Analysis |
C, 45.81; H, 2.72; Br, 12.70; Cl, 11.27; F, 3.02; N, 6.68; O, 12.71; S, 5.09
|
| CAS # |
868046-19-9
|
| Related CAS # |
868046-19-9;867365-40-0 (sodium);
|
| PubChem CID |
11527519
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
37
|
| Complexity |
977
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
ULTDEARCBRNRGR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H17BrCl2FN3O5S/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11H,2,9H2,1H3,(H,30,33)(H,31,32)
|
| Chemical Name |
N-(4-{2-[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetamido}-3-chlorobenzenesulfonyl)propanamide
|
| Synonyms |
Elsulfavirine; Elpida.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~62.5 mg/mL (~99.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.08 mg/mL (3.31 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: 10% DMSO+90% (20% SBE-β-CD in Saline): 2.08 mg/mL (3.31 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5891 mL | 7.9456 mL | 15.8912 mL | |
| 5 mM | 0.3178 mL | 1.5891 mL | 3.1782 mL | |
| 10 mM | 0.1589 mL | 0.7946 mL | 1.5891 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
